Gumalad, Gabriel .

HRN: 22-34-89  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
12/25/2022
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
12/25/2022
01/01/2023
IVT
1.8 G
8 Hrs
Autoimmune Encephalitis
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Central Nervous System    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: